Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM48K0X)

Drug Name
Carfilzomib Drug Info
Synonyms
Carfilzomib; 868540-17-4; Kyprolis; Carfilzomib (PR-171); PR-171; UNII-72X6E3J5AR; 72X6E3J5AR; CHEMBL451887; CHEBI:65347; NCGC00249613-01; DSSTox_RID_82886; DSSTox_CID_28616; DSSTox_GSID_48690; (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide
Cross-matching ID
PubChem CID
11556711
ChEBI ID
CHEMBL451887
CAS Number
CAS 868540-17-4
TTD Drug ID
D00UVA
VARIDT Drug ID
DR01324
ACDINA Drug ID
D00915

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Proteasome 2.82 0.00e+0 44/46 (95.65%) PSMC2;PSMA3;PSMB3;...
Ribosome 2.23 0.00e+0 113/158 (71.52%) RPS4Y1;RPS8;RPL35A;...
Legionellosis 2.19 0.00e+0 51/57 (89.47%) HSPA1A;CD14;HSPA6;...
Spinocerebellar ataxia 2.17 0.00e+0 128/143 (89.51%) PSMC2;PSMA3;PSMB3;...
Graft-versus-host disease 2.14 0.00e+0 32/42 (76.19%) CD86;PRF1;IL6;...
Parkinson disease 2.10 1.62e-3 176/249 (70.68%) TUBB2A;PSMC2;PSMA3;...
Prion disease 2.09 1.39e-3 209/273 (76.56%) HSPA1A;C1QA;TUBB2A;...
Protein processing in endoplasmic reticulum 2.07 1.21e-3 127/171 (74.27%) HSPA1A;HSPA6;CRYAB;...
Allograft rejection 2.05 1.08e-3 32/38 (84.21%) CD86;PRF1;TNF;...
Huntington disease 2.04 9.71e-4 233/306 (76.14%) TUBB2A;PSMC2;PSMA3;...
Autoimmune thyroid disease 2.04 8.83e-4 46/53 (86.79%) CD86;PRF1;CGA;...
Pertussis 1.97 2.43e-3 64/76 (84.21%) CD14;C1QA;C1QB;...
Amyotrophic lateral sclerosis 1.92 2.99e-3 267/364 (73.35%) SQSTM1;TUBB2A;PSMC2;...
Ribosome biogenesis in eukaryotes 1.91 3.47e-3 52/108 (48.15%) REXO2;NXT2;POP4;...
Staphylococcus aureus infection 1.90 3.89e-3 72/95 (75.79%) C1QA;C1QB;KRT16;...
Rheumatoid arthritis 1.89 3.64e-3 78/93 (83.87%) ATP6V1D;CXCL8;CTSL;...
Ferroptosis 1.88 4.00e-3 36/41 (87.8%) GCLM;SLC7A11;CP;...
Viral protein interaction with cytokine and cytokine re... 1.87 3.78e-3 84/100 (84%) CXCL10;TNFSF10;IL2RB;...
Phagosome 1.86 3.58e-3 118/152 (77.63%) CD14;TUBB2A;ATP6V1D;...
Pathways of neurodegeneration 1.86 3.40e-3 354/475 (74.53%) SQSTM1;TUBB2A;PSMC2;...
Coronavirus disease 1.84 4.63e-3 215/232 (92.67%) C1QA;C1QB;CXCL10;...
Antigen processing and presentation 1.83 4.42e-3 60/78 (76.92%) HSPA1A;HSPA6;CTSL;...
Cytokine-cytokine receptor interaction 1.82 4.22e-3 246/295 (83.39%) CXCL10;TNFSF10;INHBB;...
Salmonella infection 1.78 6.48e-3 198/249 (79.52%) CD14;TUBB2A;TNFSF10;...
Inflammatory bowel disease 1.77 8.16e-3 58/65 (89.23%) IL18;TGFB1;IL6;...
Asthma 1.76 8.59e-3 25/31 (80.65%) FCER1A;IL9;TNF;...
Alzheimer disease 1.75 8.64e-3 279/369 (75.61%) TUBB2A;PSMC2;PSMA3;...
IL-17 signaling pathway 1.71 1.60e-2 84/94 (89.36%) S100A9;CXCL10;S100A8;...
Epithelial cell signaling in Helicobacter pylori infect... 1.70 1.78e-2 62/70 (88.57%) ATP6V1D;MET;CXCL8;...
Mitophagy 1.69 1.78e-2 56/68 (82.35%) SQSTM1;GABARAPL1;RAB7A;...
Cholinergic synapse -1.73 4.27e-2 99/113 (87.61%) BCL2;ITPR1;FYN;...
Non-homologous end-joining -1.74 4.31e-2 11/13 (84.62%) POLL;RAD50;FEN1;...
Mismatch repair -1.80 2.74e-2 22/23 (95.65%) MLH1;POLD1;RFC4;...
Homologous recombination -1.80 4.10e-2 35/41 (85.37%) RAD54L;BABAM2;POLD1;...
Butanoate metabolism -2.15 0.00e+0 23/28 (82.14%) ECHS1;EHHADH;GAD1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H